Proceedings of the Pakistan Academy of Sciences: B Life and Environmental Sciences 60(4): 565-584 (2023) Copyright © Pakistan Academy of Sciences ISSN (Print): 2518-4261; ISSN (Online): 2518-427X http://doi.org/10.53560/PPASB(60-4)874



Review Article

Bioactive Compounds via *in vitro* Culture Approach and Pharmacological Attributes of Genus *Euphorbia*: A Comprehensive Review

Noor Zaman¹, Sami Ullah¹, Wadood Shah¹, Muhammad Nauman Khan^{2, 3*}, Baber Ali⁴, Amjad Ali⁵, Fethi Ahmet Ozdemir⁶, and Gaweł Sołowski^{6*}

¹Department of Botany, University of Peshawar, Peshawar 25120, Pakistan
 ²Biology Laboratory, University Public School, University of Peshawar, Peshawar 25120, Pakistan
 ³Department of Botany, Islamia College Peshawar, Peshawar 25120, Pakistan
 ⁴Department of Plant Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan
 ⁵Department of Sustainable Crop Production, Universita Cattolica del Sacro Cuore, Via Emilia, Parmense 84, Italy
 ⁶Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, 12000, Bingol, Turkey

Abstract: The family Euphorbiaceae comprises 2000 species and is listed as third among the largest flowering family. Euphorbia is used in traditional treatment for various diseases, including dengue fever, dysentery, diarrhea, and anemia. This review aims to collect data from various published literature sources for quick and effective cultivation of Euphorbia species through tissue culture and documentation of potent secondary metabolites obtained from different cultures of *Euphorbia* and its manifold pharmacological activities from various parts extracts. The data for this review were systematically collected from different scientific databases, including Google Scholar, Science Direct, PubMed, and published literature. Different secondary metabolites have been reported from the in votro culture of Euphorbia containing anthocyanin, saponins, tannins, sterols, flavonoids, glycosides, diterpenes, and sesquiterpene. The essential oils from extractions of the Euphorbia genus embraced about 80 active phytochemical constituents. The extracts and compounds exhibited different pharmacological activities, including hepato-protective, anti-fungal, anti-bacterial, and anti-cancer. Besides the pharmaceutical and importance of the genus Euphorbia, this report also described the methodologies of explant cultures, in-vitro production of biologically active compounds, and vital phytochemicals extraction from various parts of Euphorbia. Therefore, there is great attention for in-vivo studies on Euphorbia to further investigate and confirm their therapeutic effects for safe and effective medical use. The in-vitro cultivation technique needs further development, either in bioreactors or temporary immersions and shakes flasks to obtain vigorous sprouts of Euphorbia.

Keywords: Biological Activities, Bioactive Compounds, Pharmacological Relevance, *Euphorbia*, Essential Phytoconstituents, Disease Treated.

1. INTRODUCTION

Family *Euphorbiaceae* contains herbs, shrubs, trees, and succulent plants; both wild and cultivated plants of this family are found all over the globe [1]. Most of the species of this family chiefly existed in tropical regions but also predominantly

extended into temperate zones. Most species of the family *Euphorbiaceae* produce milky latex; reported as poisonous in several species (*Euphorbia tirucalli*, *Euphorbia royleana*, *Euphorbia lathyris*, *Euphorbia esula*, *Euphorbia conitofolia Euphorbia milii*, *Euphorbia hirta*, *Euphorbia neriifolia*, and *Euphorbia heliscopia*) as described previously

Received: March 2023; Revised: November 2023; Accepted: December 2023

^{*}Corresponding Authors: Muhammad Nauman Khan <nomiflora@uop.edu.pk>; Gaweł Sołowski <gawelsolowski@gmail.com>

[2-6]. In Pakistan, the family *Euphorbiaceae* is comprised of 24 genera and 90 species. Besides this, extracts obtained from various parts of the genus *Euphorbia* proved their efficiency in relieving constipation and other gastrointestinal disorders. Moreover, its cytotoxic property bears antineoplastic compounds in the forthcoming time [7]. The traditional uses in medicine and industry of the latex obtained from *Euphorbia* species are well-known. Different members of this family are extensively used for aesthetic and medicinal purposes and cultivation has significant economic importance [8].

Euphorbia hirta has been investigated with diverse medicinal properties; conventionally, used for curing different ailments like dengue fever, diarrhea, dysentery, ulcer, asthma, bronchitis, etc. The latex obtained from E. hirta is extensively used in treating jaundice, anemia, and skin disorders. Similar antipyretic potential appeared in Euphorbia neriifolia [9]. Moreover, Awaad et al. [8] investigated several pharmacological activities from different parts of E. hirta extracts, which include antispasmodic, antifungal, antibacterial, anticatarrhal, diuretic, etc. Folk medicine in Australia utilized the latex obtained from Euphorbia peplus for curing keratosis and skin cancer [10, 11]. Recently, it is widely used as an essential part of many natural and medicinal products [12]. A huge number of pharmacological attributes have also been reported from Euphorbia tirucalli [13].

Tissue culture could be defined as the sterilized culture of cells, tissues, and organs in a controlled condition. Plant tissue culture is also known as sterile culture, in vitro culture, or axenic culture; an essential and fundamental technique in commercial and applied studies [14, 15]. Plant tissue culture media contain vitamins, micronutrients, macronutrients, and all other essential components required for normal growth and development. The pH recommended for the proper culturing of cells and tissues ranges between 5.3 and 5.8 [16]. Auxin's badly affecting the *in-vitro* morphogenesis of Euphorbia nivulia. Similarly, Martin et al. [17], studied the effect of auxins and cytokinin on hypocotyltyle culture of Euphorbia esula. Plant tissue culture is becoming a pressing need of the hour to conserve endangered species through clonal propagation and production of medicinally

important plants on large scale in a controlled condition in a well-defined aseptic way [18, 19]. Extensive research has been carried out and still improvements need in the in-vitro culture technique in boosting the yield of secondary metabolites. In this literature review, we have discussed the efforts made by different phytochemists, botanists, pharmacologists, biochemical engineers, and tissue culturists for the improvement and establishment of the *in-vitro* cultivation approach of *Euphorbia* species. In a parallel review documented only the biological activity and triterpenoids content of the genus Euphorbia; however, no review analyzed the procedures for the preparation of different explant cultures, in-vitro production of biologically active compounds from various cultures, and enlisting the detailed pharmacological attributes of genus Euphorbia [20].

2. DATA COLLECTION STRATEGY

The information regarding this review was systematically collected from different scientific databases including Google Scholar, Science Direct, PubMed, and published literature. The papers selected from the base were most suitable on keywords: biological activities, pharmacological effects, *Euphorbia*, phytochemicals, and disease treated without time limitation. The 149 publications that were chosen, spanning the years 1978 to 2022, displayed remarkable findings that reflected current scientific trends at the time of publication.

3. PHYTOCHEMISTRY AND PHARMACOLOGY OF GENUS EUPHORBIA

Conventionally, the genus Euphorbia is used in treating some ailments, owing to its astonishing disease-curing properties. Recently the mesmerizing therapeutic potential of the genus Euphorbia has startled researchers, several pure compounds were also isolated from extracts of different plant parts [21]. The phytochemical screening of genus Euphorbia showed the presence of essential phytochemicals having robust therapeutic influence, other than its conventional uses it has robust medicinal properties [22], such as anti-arthritis, anti-diarrheal, analgesic, hepatoprotective and antipyretics (Table 1 in Annexure I). We provided an overview of various parts of the

species belonging to the genus *Euphorbia* (Figures 1 and 2), reflecting the importance of various parts in context to their pharmacological potential.

Whereas, the applications of whole plants or various plant parts on different animals'/cell lines have been documented (Figure 3). In addition, flavonoids, diterpenoids, triterpenoids, tannins, and polyphenols were also being isolated from some species of Euphorbia through phytochemical screening. As far as their biological activities are concerned; phytochemical responses vary greatly, in most cases diterpenoids showed anti-cancer and cytotoxic activity; flavonoids and triterpenoids proved effective in treating inflammation and inhibiting pathogenic activities. Many natural products have been derived from Euphorbia; mainly including essential oils, pure compounds, and extracts with promising biological activities. About 80 phytochemicals have been reported from essential oils of Euphorbia species and prominent secondary metabolites [23]. Furthermore, E. hirta leaves extract confirmed the presence of essential vitamins in sufficient amounts, including vitamin B2, vitamin E, and vitamin C [24].

4. IN VITRO TISSUE CULTURE APPROACHES IN GENUS EUPHORBIA

Family *Euphorbiaceae* contains a large number of species; including many endangered and endemic species. Though, in vitro cultivation is limited to some specific genera having medicinal, aesthetic, food, rubber, and dye-yielding purposes [25]. *In vitro* culture is a conducive and effective technique for the proliferation and conservation of endangered species in a shorter period, mainly for those plants which are difficult to be grown by using conventional methods of cultivation and conservation [26]. Plants regenerated through in vitro culture possess some advantageous features over those cultivated in fields via conventional agricultural practices. For instance, the culturedgrown mountain arnica rhizome has a characteristic smell and taste, lacking in the same plant rhizome cultivated in field conditions. Several active phytochemicals were isolated from different plant parts and propagated via cell, tissue, and hair root culture methods [27]. It is immensely important to select a parent plant with a considerable amount of biologically active phytochemicals for callus formation; likewise, selecting those cell lines with higher yield [28]. Succeeding reports on cell culture, callus culture, shoot, leaf, and root culture, somatic embryogenesis, and nodal/inter nodal culture of genus Euphorbia (Table 2 in Annexure II).

5. CALLUS CULTURE OF GENUS EUPHORBIA

A callus is a mass of tissues having differentiated cells, developed under the influence of determinate hormonal control described previously [29, 30]. Propagated callus and shoot from stem pieces of *Euphorbia esula* HR lines and shoot regeneration from hypocotyls of non-HR lines. Maximum shoot regeneration was observed by inoculating the explants in a growth medium containing Murashige and Skoog (MS) basal salts, MS + vitamins, 1.11 μ M 6-benzylaminopurine, 1.97 μ M indole-3-butyric acid, and 3.0 % sucrose, pH 5.6–5.8. After 30 days multiple shoots developed from the stem (Figure 4).



Fig. 1. Major secondary metabolites reported in Euphorbia species.



Fig. 2. Percentage of various parts of *Euphorbia* species used in pharmacology (**a**) *Euphorbia hirta* (**b**) *Euphorbia nerrifolia* (**c**) *Euphorbia helioscopia* (**d**) *Euphorbia tirucalli* (**e**) *Euphorbia antiquorum* (**f**) *Euphorbia milli* (**g**) *Euphorbia pulcherrima* (**h**) *Euphorbia characias.*

The callus culture of *Euphorbia hirta* revealed the presence of phenolic and sterol compounds with a substantial amount of chlorogenic acid (79.67 mg/100 g d. m.) syringic acid (32.57 mg/100 g d. m.) and brassicasterol (32.57 mg/100 g d. m.) by Özbilgin et al. [31] and Lone et al. [32]. Euphorbia tirucalli callus culture revealed the presence of euphol, tirucallol, and 4, 4-dimethyl sterols amount [33, 34]. The most prominent secondary metabolites extracted from cultured cells of *Euphorbia* species include cyanidin glycoside

from *Euphorbia milli*. Similarly, the sitosterol, palmitic acid, and triterpenoids from cultured cells of *E. esula*, and phytosterol, tirucallol, triterpene, and euphol (Table 3 in Annexure III) extracted from callus cultured cells of *Euphorbia tirucalli* [33, 35]. *Euphorbia characias* callus culture hormonal regulation of triterpinols formation was investigated [36]. Leaf explants of *E. hirta* were cultured on MS+NAA and 6-benzylaminopurine (BAP) medium, at the onset of callus initiation, it was again subcultured on the same media with 1





Fig. 3. Percentage of animals/cell lines used for the assessment of various pharmacological activities of euphorbia genus different parts extracts (**a**) *Euphorbia hirta* (**b**) *Euphorbia nerrifolia* (**c**) *Euphorbia kansui* (**d**) *Euphorbia hilioscopia* (**e**) *Euphorbia tirucalli* (**f**) *Euphorbia antiquorum* (**g**) *Euphorbia milli* (**h**) *Euphorbia pulcherrima* (**i**) *Euphorbia characias*.

mg/L concentration of NAA (1-naphthaleneacetic acid) and BAP [30]. Red callus was produced from apical and axillary buds of *E. pulcherrima* on MS basal medium containing benzyladenine (BA) and a combination of IAA (indole acetic acid) (IAA) and BA [37]. From leaf explant of *E. helioscopia* callus was induced via Murashige and Skoog's (MS) medium supplemented with 6-benzylaminopurine [38]. Furthermore, secondary metabolite extraction is of utmost importance in culturally grown plants; making it an ideal technique for raising plants for commercial and medicinal purposes [29].

6. SHOOT, LEAF, SEED, AND ROOT REGENERATION VIA DIFFERENT CULTURES

Murashige and Skoog's (MS) + naphthaleneacetic acid (NAA) medium was used to produce roots from *E. tannensis* shoot culture, some of the seedlings were kept under glasshouse in pots containing coarse sand, peat, and perlite with a ratio of 6:3:1, respectively. The plantlets remained healthy and grew well under the glasshouse. On contrary, when placed in peat blocks all seedlings wilted and



Fig. 4. In vitro regeneration of leafy spurge (*Euphorbia esula* L.) a = Large callus with a loose structure, <math>b = Shoot regeneration from hypocotyls of non-HR lines, c = Shoots regeneration from stem pieces of HR lines, d = Callus, e = Callus and shoot primordium, f = Multiple shoots regenerated from the wounded surface of explants, g = Multiple plantlets growing from calluses, h = Plantlets developing roots in rooting medium. (i) Plantlets growing *In-vitro*.

collapsed. In comparison with E. tannensis; in-vitro root formation from shoots of E. lathyris was quite slow on the same medium used for the formation of roots from E. tannensis shoots [39]. Euphorbia antisyphilitica shoots were propagated via in*vitro* culture technique by using BAP (4.44 μ M) and MS + NAA (0.13 μ M) medium, root progress was satisfactory and when transferred to the field; easily adapted to the natural climatic conditions [31]. Euphorbia lagascae shoots were regenerated through tissue culture technique; afterward, dipped in IBA (50 mg/L) for a period of 2 minutes, an increase of 70% to 100% survival rate was observed with the application of benzyladenine (BA) [40]. Tips of Euphorbia pugniformis cristate lateral shoots were cultured by using MS + NAA (0.1 mg/L) sucrose 2.0% and IBA in culture media; as a result, both of the normal and cristate types of shoots were produced. 90%-100% of cultured plantlets successfully acclimatized outside the laboratory in field conditions [41]. In-vitro propagation of Euphorbia fulgens micro shoot cuttings and their adjustment to the natural climatic conditions were

established [42]. *Euphorbia pulcherrima* shoot buds were propagated through the tissue culture technique [43]. Shoots were raised from nodal shoot explant of *Euphorbia pulcherrima* (Figure 5) using a medium having 6-benzylaminopurine (BAP) in combination with adenine sulfate and GA3 (Gibberellic acid).

The induction of shoot was optimal by using BAP at 0.5 mg/L in combination with 20 mg/L adenine sulfate. Numerous roots and the highest frequency (77.8%) were observed by using MS media and supplements of 1.0 mg/L indole-acetic acid (IAA) by Sreenika *et al.* [44]. *E. esula* hypocotyl segment was applied as explant and roots were proliferated on culture media containing IAA and IBA [45]. Leaf-cultured cells of *Euphorbia milli* showed the presence of a red colour pigment mainly consisting of anthocyanin [46, 47]. Extract of leaves of *Euphorbia cotinofolia* in streptomycin possessed wide range of flavonoids, terpenoids, and steroids that help remove a pathogenic form of *Bacillus cereus, Bacillus subtilis, Escherichia coli*,



Fig. 5. Adventitious shoot formation from callus of *Euphorbia pulchurrima* (a = Green shoot primordia, b = Elongating Shoots.

Enterobacter aerogenes, Klebsiella pneumoniae, Salmonella typhi, and *Staphylococcus aureus* [48]. Amorphous calcium phosphate nanoparticles (ACP NPs) with coumarin extracts from seeds of *Euphorbia lathyris* possessed strong cytotoxicity against colon cancer [49].

7. SOMATIC EMBRYOGENESIS NODAL AND INTER NODAL CULTURES OF GENUS *EUPHORBIA*

Cultivation through somatic embryogenesis provides a prospect to propagate those lines bearing superior quality in terms of secondary metabolites and yield attributes [43]. To date, propagation through cell suspension culture, callus culture, and somatic embryogenesis was described in several *Euphorbia* species. The somatic embryogenesis of *Euphorbia pulcherrima* was investigated [42]. From the hypocotyl of *Euphorbia pulcherrima* somatic embryo formation was reported by Biesboer *et al.* [50]. *Euphorbia tirucalli* internodal explants (Figure 6) were propagated via *in-vitro* culture technique by using Linsmaier and Skoog's (LS) + TDZ (0.02 mg/L) culture medium [51].

Euphorbia pulcherrima nodal explants were cultured on NAA + MS, isopentenyl adenine (2iP), and Kin media [52]. *Euphorbia pulcherrima* nodal explant on MS + α -naphthalene acetic acid and isopentenyl adenine (2-iP) medium gave rise to somatic embryos [53]. Internode explant of *E. hirta* gave rise to a higher number of somatic embryos on BAP and Kin media supplemented with indole-acetic acid (IAA) and naphthalene acetic acid (NAA). NAA proved more productive than indole-acetic acid (IAA) with a higher percentage of somatic embryos. 100% response was noticed by using MS in combination with 0.5 mg/L naphthalene acetic acid (NAA), 0.4 mg/L each of BAP, and kinetin (Kin). Medium with IAA in place of NAA gave maximum (92%) somatic embryo induction [54, 55].

8. INFLORESCENCE TISSUE CULTURE

Das *et al.* [56] manipulated the inflorescence of explants (*Euphorbia milli*) for their *in-vitro* propagation. Consequently, vegetative meristems were cultivated from the meristems of an inflorescence of the main axis after one week of inoculation on MS medium supplemented with indole-3-butyric acid (IBA) and benzyl adenine (BA). Among various growth regulators, MS medium with 1.0 mg/L BA and 0.3 mg/L IBA responded better in terms of callus initiation with a maximum percentage of leaf and shoot developed.

9. CONCLUSIONS

In this review, pharmacological activities, methodologies of preparing different explant cultures, *in-vitro* production of biologically active compounds, and vital phytochemicals extracted from various parts of the genus *Euphorbia* has been documented. For successful *in-vitro* propagation of seedlings; media composition, plant growth regulators (PGRs) selection, and other vital requirements such as temperature, light, and pH are immensely important to be determined. Moreover,



Fig. 6. Plant regeneration from internode segments of E. tirucalli. (a = Adventitious buds, b = Trunk-shaped shoots c = whole plantlet.

the plants regenerated through tissue culture need to be assessed for their safety in living organisms is also necessary for higher marketability and significance. Besides this, investigating the potential of preventing diseases by applying *Euphorbia* should be a relevant issue. Disease prevention methods and modern cultivation practices for *Euphorbia* need to be further elucidated with the application of advanced techniques like hydroponic, aeroponic, and plugged seedling culture methods that should be adopted for rapid growth and better quality of *Euphorbia* species. Still, there is a great need for an imperative propagative method and an immense desire for the swift proliferation of superior qualities of *Euphorbia* species.

10. FUTURE PERSPECTIVES AND RECOMMENDATIONS

The identification and isolation of novel bioactive chemicals from the genus *Euphorbia* should be the focus of future study. Analytical advances such as mass spectrometry and nuclear magnetic resonance can help with the isolation and structural elucidation of previously unknown substances. Further optimisation of *in vitro* culture conditions is required to maximise bioactive chemical synthesis. This includes optimising nutrient formulas, growth regulators, and culture medium components to mimic the natural environment and increase target compound yield. Exploring biotechnological technologies for large-scale synthesis of bioactive substances, such as plant cell and tissue culture, can provide a sustainable and controlled supply. This could include the development of bioreactor systems and commercial scale-up initiatives. More thorough pharmacological investigations on isolated chemicals from *Euphorbia* species are required to fully grasp their medicinal potential. Following clinical trials, their efficacy, safety, and prospective applicability in treating various diseases can be validated.

Promote interdisciplinary collaborations geneticists, pharmacologists, between biotechnologists, and other experts. Such collaborations have the potential to speed research and bring varied perspectives to bear on the issues connected with the study of Euphorbia species as well as establish standardized protocols for the extraction of bioactive compounds from Euphorbia plants. This will assure uniformity in research outputs and make it easier to compare results across investigations. Finally, the possibilities for future study on bioactive substances from the genus Euphorbia are encouraging, with opportunities for scientific improvements, biotechnological innovations, and sustainable practices. Implementing the recommended procedures can aid in the discovery of novel treatments, the conservation of plant species, and the promotion of responsible resource use.

11. CONFLICT OF INTEREST

The authors declare no conflict of interest.

12. REFERENCES

- A. Wal, P. Wal, N. Gupta, G. Vishnoi, and R. Srivastava. Medicinal value of *Euphorbia tirucalli*. *International Journal of Pharmaceutical and Biological* 4(1): 31-40 (2013).
- T.J. Mwine, P. and Van Damme. *Euphorbia tirucalli* L.(Euphorbiaceae): the miracle tree: current status of available knowledge. *Scientific Research and Essays* 6: 4905-4914 (2011).
- A.S. Ioannidis, K.I. Papageorgiou, and P.S. Andreou. Exposure to *Euphorbia lathyris* latex resulting in alkaline chemical injury: a case report. *Journal of Medical Case Reports* 3: 1-3 (2009).
- R.A. de Matos, T. da Silva Cordeiro, R.E. Samad, N.D. Vieira Jr, and L.C. Courrol. Green synthesis of stable silver nanoparticles using *Euphorbia milii* latex. *Colloids and Surfaces A. Physicochemical and Engineering Aspects* 389: 134-137 (2011).
- S. Kumar, R. Malhotra, and D. Kumar. *Euphorbia hirta*: Its chemistry, traditional and medicinal uses, and pharmacological activities. *Pharmacognosy Reviews* 4: 58 (2010).
- S. Al-Sultan, and Y.A. Hussein. Acute toxicity of Euphorbia heliscopia in rats. Pakistan Journal of Nutrition 5: 135-140 (2006).
- A.T. Khalil, Z.K. Shinwari, M. Qaiser, and K.B. Marwat. Phyto-therapeutic claims about euphorbeaceous plants belonging to Pakistan; an ethnomedicinal review. *Pakistan Journal of Botany* 46: 1137-1144 (2014).
- A.S. Awaad, M.R. Alothman, Y.M. Zain, G.M. Zain, S.I. Alqasoumi, and D.A. Hassan. Comparative nutritional value and antimicrobial activities between three *Euphorbia* species growing in Saudi Arabia. *Saudi Pharmaceutical Journal* 25: 1226-1230 (2017).
- A. Sultana, M.J. Hossain, M.R. Kuddus, M.A. Rashid, M.S. Zahan, S. Mitra, A. Roy, S. Alam, M.M.R. Sarker, and I. Naina Mohamed. Ethnobotanical Uses, Phytochemistry, toxicology, and pharmacological properties of *Euphorbia neriifolia* Linn. against infectious diseases: A comprehensive review. *Molecules* 27: 4374 (2022).
- C.L. Zhao, W.I. Chik, and H.J. Zhang. Bioprospecting and bioassay-guided isolation of medicinal plants—A tool for drug discovery. In: Evidence-Based Validation of Herbal Medicine. P. Mukherjee (Ed.), *Elsevier*, pp. 511-537 (2022).
- N.H. Khan, M. Mir, L. Qian, M. Baloch, M.F.A. Khan, E.E. Ngowi, D.D. Wu, and X.Y. Ji. Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures. *Journal of Advanced Research* 36: 223-247 (2022).
- M. Ernst, O.M. Grace, C.H. Saslis-Lagoudakis, N. Nilsson, H.T. Simonsen, and N. Rønsted. Global medicinal uses of *Euphorbia* L. (Euphorbiaceae). *Journal of Ethnopharmacology* 176: 90-101 (2015).
- 13. B. Upadhyay, K. Singh, and A. Kumar. Ethno-

medicinal, phytochemical and antimicrobial studies of *Euphorbia tirucalli* L. *Journal of Phytology* 2(4): 65-77 (2010).

- 14. T.A. Thorpe. History of plant tissue culture. *Molecular Biotechnology* 37: 169-180 (2007).
- 15. M. Adil, and B.R. Jeong. In vitro cultivation of *Panax ginseng* CA Meyer. *Industrial Crops and Products* 122: 239-251 (2018).
- A. Hussain, I.A. Qarshi, H. Nazir, and I. Ullah. Plant tissue culture: current status and opportunities. In: Recent Advances in Plant in vitro Culture. A. Leva, and L.M.R. Rinaldi (Ed.), *IntechOpen* 6: 1-28 (2012).
- K. Martin, C. Sunandakumari, M. Chithra, and P. Madhusoodanan. Influence of auxins in direct in vitro morphogenesis of *Euphorbia nivulia*, a lectinaceous medicinal plant. *In vitro Cellular and Developmental Biology-Plant* 41: 314-319 (2005).
- D.G. Davis, P.A. Olson, and R.L. Stolzenberg. Organogenesis in cell cultures of leafy spurge (Euphorbiaceae) accessions from Europe and North America. *Plant Cell Reports* 7: 253-256 (1988).
- 19. K.M. Davies, and S.C. Deroles. Prospects for the use of plant cell cultures in food biotechnology. *Current Opinion in Biotechnology* 26: 133-140 (2014).
- D. Kemboi, X. Peter, M. Langat, and J. Tembu. A review of the ethnomedicinal uses, biological activities, and triterpenoids of Euphorbia species. *Molecules* 25: 4019 (2020).
- 21. R. Benjamaa, A. Moujanni, N. Kaushik, E.H. Choi, A.K. Essamadi, and N.K. Kaushik. *Euphorbia* species latex: A comprehensive review on phytochemistry and biological activities. *Frontiers in Plant Science* 13: 1008881 (2022).
- 22. O.A. Pascal, A.E.V. Bertrand, T. Esaïe, H.A.M. Sylvie, and A.Y. Eloi. A review of the ethnomedical uses, phytochemistry and pharmacology of the *Euphorbia* genus. *The Pharma Innovation* 6(1): 34-39 (2017).
- B. Salehi, M. Iriti, S. Vitalini, H. Antolak, E. Pawlikowska, D. Kręgiel, J. Sharifi-Rad, S.I. Oyeleye, A.O. Ademiluyi, and K. Czopek. Euphorbia-derived natural products with potential for use in health maintenance. *Biomolecules* 9(8): 337 (2019).
- 24. M.J.N.M. Ureta, I.N.A. Perez, V.M.C. Carmona, and R. Ureta. Potent application of the lyophilized aqueous leaf extract of *Euphorbia hirta* (Tawa-Tawa) in the development of a naturally flavored Ice cream. *World News of Natural Sciences*, pp. 21 (2018).
- U. Saleem, B. Ahmad, M. Ahmad, K. Hussain, and N.I. Bukhari. Anti-nociceptive, anti-inflammatory and anti-pyretic activities of latex and leaves methanol extract of *Euphorbia helioscopia*. *Asian Pacific Journal of Tropical Disease* 5: 322-328 (2015).
- 26. U. Saleem, M. Saleem, B. Ahmad, K. Hussain, M. Ahmad, N. Bukhari, and A.Anjum. In-vitro

antimicrobial susceptibility testing of leaves methanol extract and latex of *euphorbia helioscopia* using agar well diffusion and broth dilution methods. *Journmal of Animals and Plant Sciences* 25: 261-267 (2015).

- 27. U. Saleem, B. Ahmad, M. Ahmad, K. Hussain, and N.I. Bukhari. Investigation of in vivo antioxidant activity of *Euphorbia helioscopia* latex and leaves methanol extract: a target against oxidative stress induced toxicity. *Asian Pacific Journal of Tropical Medicine* 7: S369-S375 (2014).
- Y. Cai, J. Wang, and B. Liang. Antitumor activity of the root of *Euphorbia helioscopic* in vitro. *Zhong yao cai= Zhongyaocai= Journal of Chinese Medicinal Materials* 22(2): 85-87 (1999).
- Z. Hussain, A. Waheed, R.A. Qureshi, D.K. Burdi, E.J. Verspohl, N. Khan, and M. Hasan. The effect of medicinal plants of Islamabad and Murree region of Pakistan on insulin secretion from INS-1 cells. *Phytotherapy Research* 18(1): 73-77 (2004).
- D.G. Davis, and P.A. Olson. Organogenesis in leafy spurge (*Euphorbia esula* L.). *In vitro Cellular and Developmental Biology-Plant* 29: 97-101 (1993).
- S. Özbilgin, E.K. Akkol, I. Süntar, M. Tekin, and G.S. İşcan. Wound-healing activity of some species of *Euphorbia L. Records of Natural Products* 13: 104-113 (2019).
- B.A. Lone, M. Chishti, F.A. Bhat, H. Tak, S.A. Bandh. In vitro and in vivo anthelmintic activity of *Euphorbia helioscopia* L. *Veterinary Parasitology* 189: 317-321 (2012).
- k. Ohyama, N. Misawa, Y. Yamano, and T. Komano. Protoplast isolation from *Euphorbia tirucalli* L. cell suspension cultures and sustained cell division. *Zeitschrift für Pflanzenphysiologie* 113: 367-370 (1984).
- 34. R.A. Samkumar, D. Premnath, and R. David Paul Raj. Strategy for early callus induction and identification of anti-snake venom triterpenoids from plant extracts and suspension culture of *Euphorbia hirta* L. 3 *Biotechology* 9(7): 266 (2019).
- 35. B. Munro, Q.V. Vuong, A.C. Chalmers, C.D. Goldsmith, M.C. Bowyer, and C.J. Scarlett. Phytochemical, antioxidant and anti-cancer properties of *Euphorbia tirucalli* methanolic and aqueous extracts. *Antioxidants* 4: 647-661 (2015).
- N.A. Al-Zanbagi, A.E.A. Banaja, and J. Barrett. Molluscicidal activity of some Saudi Arabian Euphorbiales against the snail *Biomphalaria pfeifferi. Journal of Ethnopharmacology* 70: 119-125 (2000).
- 37. K.H. Park, D.S. Koh, S.H. Lee, I.M. Jung, K.H. Kim, C.H. Lee, K.H. Kim, and Y.H. Lim. Anti-allergic and anti-asthmatic activity of helioscopinin-A, a polyphenol compound, isolated from *Euphorbia helioscopia*. *Journal of Microbiology and Biotechnology* 11: 138-142 (2001).
- 38. K.J. Evenson, D. Galitz, and D. Davis. The relationship of nitrogen source and in vivo nitrate

reductase actiity to root formation in *Euphorbia* esula cell suspension cultures. *Plant Cell Reports* 7: 361-364 (1988).

- K. Ohyama, Y. Uchida, N. Misawa, T. Komano, M. Fujita, and T. Ueno. Oil body formation in *Euphorbia tirucalli* L. cell suspension cultures. *Plant Cell Reports* 3: 21-22 (1984).
- T. Jyothi, K. Shankariah, K. Prabhu, S. Lakshminarasu, G. Srinivasa, and S.S. Ramachandra. Hepatoprotective and antioxidant activity of *Euphorbia tirucalli. Iranian Journal of Pharmacology and Therapeutics* 7(1): 25-30 (2008).
- F. Pintus, D. Spanò, C. Mascia, A. Macone, G. Floris, and R. Medda. Acetylcholinesterase inhibitory and antioxidant properties of *Euphorbia characias* latex. *Records of Natural Products* 7: 147-151 (2013).
- 42. M.Airò, G.Zizzo, and B.Ruffoni. In vitro propagation of an Euphorbia milii hybrid. In: Proceedings of the II International Symposium on Acclimatization and Establishment of Micropropagated Plants 748: 241-246 (2004).
- S. Bidarigh, and E. Azarpour. Evaluation effect of BA hormone levels of poinsettia under in-vitro culture condition. *Journal of Agricultural and Biological Science* 8: 57-59 (2013).
- 44. G. Sreenika, K.S. Naga, B.V.S. Lakshmi, P. Thulja, and M. Sudhakar. Antioxidant and antitumor activity of *Euphorbia milii* flower extract against in vivo breast cancer and colon cancer in mice. *World Journal of Pharmacy and Pharmaceutical Science* 4: 912-934 (2015).
- 45. S. Bani, A. Kaul, B. Khan, V.K. Gupta, N.K. Satti, K.A. Suri, and G.N.Qazi. Anti-arthritic activity of a biopolymeric fraction from *Euphorbia tirucalli*. *Journal of Ethnopharmacology* 110: 92-98 (2007).
- A. Singh, and S.K. Singh. Molluscicidal evaluation of three common plants from India. *Fitoterapia* 76: 747-751 (2005).
- 47. N. Kumar, and Reddy. In vitro plant propagation: a review. *Journal of Forest and Environmental Science* 27: 61-72 (2011).
- 48. R. Mallón, J. Rodríguez-Oubiña, and M.L. González. In vitro propagation of the endangered plant Centaurea ultreiae: assessment of genetic stability by cytological studies, flow cytometry and RAPD analysis. *Plant Cell, Tissue and Organ Culture (PCTOC)* 101: 31-39 (2010).
- B. Kleffel, and W. Preil. Studies on embryogenesis in suspension culture of poinsettia (*Euphorbia pulcherrima*). In: *Proceedings of the 6th International Congress of Plant Tissue Cell Culture*, p. 294 (1986).
- D.D. Biesboer, and P.G. Mahlberg. The effect of medium modification and selected precursors on sterol production by short-term callus cultures of *Euphorbia tirucalli. Journal of Natural Products* 42: 648-657 (1979).
- 51. H. Uchida, O. Nakayachi, M. Otani, M. Kajikawa, Y. Kohzu, K.T. Yamato, H. Fukuzawa, T. Shimada,

and K. Ohyama. Plant regeneration from internode explants of *Euphorbia tirucalli*. *Plant Biotechnology* 21: 397-399 (2004).

- M. Fernandes-Ferreira, M.S. Pais, and J. Novais. The effects of medium composition on biomass, sterols and triterpenols production by in-vitro cultures of *Euphorbia characias*. *Bioresource Technology* 42: 67-73 (1992).
- K.K. Singh, G.P. Rauniar, and H. Sangraula. Experimental Study of Anticonvulsive Effects of *Euphorbia Pulcherrima* in Mice. *WebmedCentral*, *Pharmacology* 2(11): WMC002486 (2011).
- 54. V. Madhavan, A. Murali, D.S. Lalitha, and S. Yoganarasimhan. Studies on anti-hyperglycemic effect of *Euphorbia antiquorum* L. root in diabetic rats. *Journal of Intercultural Ethnopharmacology* 4: 308 (2015).
- 55. R. Giordani, J. Trebaux, M. Masi, and P. Regli. Enhanced antifungal activity of ketoconazole by *Euphorbia characias* latex against Candida albicans. *Journal of Ethnopharmacology* 78: 1-5 (2001).
- B. Das, S. Alam, R. Bhattacharjee, and B.K. Das. Analgesic and anti-inflammatory activity of *Euphorbia antiquorum* Linn. *American Journal of Pharmacology and Toxicology* 10: 46 (2015).
- 57. P.K. Pati, P. Kaushik, M. Khan, and P. Khare. Biodiversity and Ecosystem Services of Trees Outside Forests: A Case Study from Dr. Harisingh Gour Vishwavidyalaya, Sagar, Central India. *Indian Journal of Ecology* 49: 608-615 (2022).
- R. Kondamudi, K.S.R. Murthy, and T. Pullaiah. Euphorbiaceae-a critical review on plant tissue culture. *Tropical and Subtropical Agroecosystems* 10: 313-335 (2009).
- P. Chaudhary, and P. Janmeda. Quantification of phytochemicals and in vitro antioxidant activities from various parts of *Euphorbia neriifolia* Linn. *Journal of Applied Biology and Biotechnology* 10: 133-145 (2022).
- 60. H. Cui, and G. Liu. How noncoding RNAs contribute to macrophage polarization. In: MicroRNAs and Other Non-Coding RNAs in Inflammation, C.M. Greene (Ed.), *Springer*, pp. 59-84 (2015).
- 61. S. Baburaj, R. Dhamotharan, and K. Santhaguru. Regeneration in leaf callus cultures of *Euphorbia hirta* Linn. *Current Science* 56(4): 194 (1987).
- B. Xu, W. Dai, and W.S. Chao. An efficient method for in vitro regeneration of leafy spurge (*Euphorbia* esula L.). In Vitro Cellular and Developmental Biology-Plant 44(6): 548-556 (2008).
- 63. T. Lee, and A. Starratt. Growth substance requirements and major lipid constituents of tissue cultures of *Euphorbia esula* and *E. cyparissias*. *Canadian Journal of Botany* 50: 723-726 (1972).
- 64. M.B. Pisano, S. Cosentino, S. Viale, D. Spanò, A. Corona, F. Esposito, E. Tramontano, P. Montoro, C.I.G. Tuberoso, and R. Medda. Biological activities of aerial parts extracts of *Euphorbia characias*. *BioMed Research International* 2016: 1538703

(2016).

- H. Sharif, M. Mukhtar, Y. Mustapha, G. Baba, and A. Lawal. Acute and subchronic toxicity profile of *Euphorbia pulcherrima* methanol extract on Wistar albino rats. *Advances in Pharmaceutics* 2015(4): 1-9 (2015).
- 66. Z.S. Yang, G.D. Chen, Y.X. Li, and J. Chen. Characterization of callus formation in leaf of *Euphorbia helioscopia*. *African Journal of Plant Science* 3: 122-126 (2009).
- J. Tideman, and J. Hawker. In vitro propagation of latex-producing plants. *Annals of* Botany 49: 273-279 (1982).
- 68. J.L. Jakobek, R.A. Backhaus, and K. Herman. Micropropagation of candelilla, *Euphorbia antisyphilitica* Zucc. *Plant Cell, Tissue and Organ Culture* 7: 145-148 (1986).
- 69. A. Ibáñez-Torres. Rooting experiments with Euphorbia lagascae cuttings. *Anales de Biología* 26: *101-104* (2004).
- G. Balotis, and M. Papafotiou. Micropropagation and stability of *Euphorbia pugniformis* cristate form. *Acta Horticulturae* 616: 471-474 (2003).
- K. Nataraja. In vitro production of shoot buds in Euphorbia pulcherrima. Current Science 42: 577-578 (1973).
- 72. Y. Guan, S.G. Li, X.F. Fan, and Z.H. Su. Application of somatic embryogenesis in woody plants. *Frontiers in Plant Science* 7: 938 (2016).
- 73. G.H. Danial, and D.A. Ibrahim. Efficient protocol of micropropagation, and organogenesis of *Euphorbia pulcherrima* willd. plants via stem and leaf segments. *International Journal of Advanced Engineering Research and Science* 3: 236822 (2016).
- 74. D.G. Davis, and P.A. Olson. Effects of putrescine and inhibitors of putrescine biosynthesis on organogenesis in *Euphorbia esula* L. *In Vitro Cellular & Developmental Biology-Plant* 30: 124-130 (1994).
- 75. Y. Yamamoto, R. Mizuguchi, and Y. Yamada. Selection of a high and stable pigment-producing strain in cultured *Euphorbia millii* cells. *Theoretical and Applied Genetics* 61: 113-116 (1982).
- K.A. Pickens, Z. Cheng, and R.N. Trigiano. Axillary bud proliferation and organogenesis of *Euphorbia pulchurrima* winter rose. *In Vitro Cellular and Developmental Biology-Plant* 41: 770-774 (2005).
- 77. B. Jayalakshmi, K. Raveesha, and K. Amruthesh. Isolation and characterization of bioactive compounds from *Euphorbia cotinifolia*. *Future Journal of Pharmaceutical Sciences* 7: 1-9 (2021).
- 78. C. Mesas, V. Garcés, R. Martínez, R. Ortiz, K. Doello, J.M. Dominguez-Vera, F. Bermúdez, J.M. Porres, M. López-Jurado, and C. Melguizo. Colon cancer therapy with calcium phosphate nanoparticles loading bioactive compounds from *Euphorbia lathyris*: In vitro and in vivo assay. *Biomedicine and Pharmacotherapy* 155: 113723 (2022).
- 79. N. Osternack, K. Saare-Surminski, W. Preil,

and R. Lieberei. Induction of somatic embryos, adventitious shoots and roots in hypocotyl tissue of *Euphorbia pulcherrima* Willd. ex Klotzsch: Comparative studies on embryogenic and organogenic competence. *Angewandte Botanik* 73: 197-201 (1999).

- Y.T. Jasrai, K. Thaker, and M. D'Souza. *In vitro* Propagation of *Euphorbia pulcherrima* Willd. Through Somatic Embryogenesis. *Plant Tissue Culture* 13(1): 31-36 (2003).
- M. Castellanos, J.B. Power, and M.R. Davey. Somatic embryogenesis in red-and white-bract cultivars of poinsettia. *Propag Ornam Plants* 6: 9-14 (2006).
- M.S. Shekhawat, M. Manokari, and J. Revathi. Optimization of in vitro conditions for induction of somatic embryos and regeneration of plantlets in *Euphorbia hirta* L. *Current Trends in Biotechnology and Pharmacy* 12: 85-95 (2018).
- 83. Y.H. Dewir, D. Chakrabarty, E.J. Hahn, and K.Y.Paek. Flowering of Euphorbia millii plantlets in vitro as affected by paclobutrazol, light emitting diodes (LEDs) and sucrose. In Proceedings of the Proceedings of the International Symposium on Plant Biotechnology: From Bench to Commercialization. *International Society for Horticultural Science* 2006: 169-173 (2007).
- 84. D. Kapadiya, A. Singh, A. Bhandari, A. Patel, and K. Patel. Development of in vivo Plant Propagation Protocol in *Euphorbia milii* var. 'Pink Bold Beauty'. *International Journal of Current Microbiology and Applied Science* 6: 141-149 (2017).
- K.H. Lee, Y.S. Chen, J.P. Judson, S. Chakravarthi, Y.M. Sim, and H.M. Er. The effect of water extracts of *Euphorbia hirta* on cartilage degeneration in arthritic rats. *Malaysian Journal of Pathology* 30: 95-102 (2008).
- V. Pratheepa, and N. Sukumaran. Specific and nonspecific immunostimulation study of *Euphorbia hirta* on Pseudomonas fluorescens-infected Cyprinus carpio. *Pharmaceutical Biology* 49: 484-491 (2011).
- 87. H. Anuradha, B. Srikumar, N. Deepti, B. Shankaranarayana Rao, and M. Lakshmana. Restoration of acetylcholinesterase activity by *Euphorbia hirta* in discrete brain regions of chronically stressed rats. *Pharmaceutical Biology* 48: 499-503 (2010).
- 88. S. Suganya, D. Sophia, C.A. Raj, M.A. Rathi, L. Thirumoorthi, P. Meenakshi, D.G. Kumar, and V.K. Gopalakrishnan. Amelioration of nitrobenzene-induced nephrotoxicity by the ethanol extract of the herb *Euphorbia hirta. Pharmacognosy Research* 3(3): 201-207 (2011).
- S. Hore, V. Ahuja, G. Mehta, P. Kumar, S. Pandey, and A. Ahmad. Effect of aqueous *Euphorbia hirta* leaf extract on gastrointestinal motility. *Fitoterapia* 77: 35-38 (2006).
- 90. S.M. Firdous, and D. Sautya. Medicinal Plants with

Wound-Healing Potential. *Bangladesh Journal of Pharmacology* 13: 41-52 (2018).

- S.K.K. Sundari, C.T. Kumarappan, A. Jaswanth, and R. Valarmathy. Bronchodilator effect of alcoholic extract of *Euphorbia hirta* linn. *Ancient Science of Life* 23: 1 (2004).
- 92. M.A.B. Rajeh, Y.P. Kwan, Z. Zakaria, L.Y. Latha, S.L. Jothy, and S. Sasidharan. Acute toxicity impacts of *Euphorbia hirta* L. extract on behavior, organs body weight index and histopathology of organs of the mice and Artemia salina. *Pharmacognosy Research* 4: 170 (2012).
- 93. W.C. Tayone, J.C. Tayone, and M. Hashimoto. Isolation and structure elucidation of potential Anti-Dengue metabolites from Tawa-Tawa (*Euphorbia hirta* Linn.). Walailak Journal of Science and Technology (WJST) 11: 825-832 (2014).
- 94. M. Youssouf, P. Kaiser, M. Tahir, G. Singh, S. Singh, V. Sharma, N. Satti, S. Haque, and R. Johri. Antianaphylactic effect of *Euphorbia hirta*. *Fitoterapia* 78: 535-539 (2007).
- 95. S.P. Subramanian, S. Bhuvaneshwari, and G.S. Prasath. Antidiabetic and antioxidant potentials of Euphorbia hirta leaves extract studied in streptozotocin-induced experimental diabetes in rats. *General Physiology and Biophysics* 30(3): 278-285 (2011).
- M.C. Lanhers, J. Fleurentin, P. Dorfman, F. Mortier, and J.M. Pelt. Analgesic, antipyretic and antiinflammatory properties of *Euphorbia hirta*. *Planta Medica* 57: 225-231 (1991).
- 97. S. Perumal, and R. Mahmud. Chemical analysis, inhibition of biofilm formation and biofilm eradication potential of *Euphorbia hirta* L. against clinical isolates and standard strains. *BMC Complementary and Alternative Medicine* 13: 1-8 (2013).
- 98. A. Annamalai, V. Christina, D. Sudha, M. Kalpana, and P. Lakshmi. Green synthesis, characterization and antimicrobial activity of Au NPs using *Euphorbia hirta* L. leaf extract. *Colloids and Surfaces B: Biointerfaces* 108: 60-65 (2013).
- 99. N. Sharma, K.W. Samarakoon, R. Gyawali, Y.H. Park, S.J. Lee, S.J. Oh, T.H. Lee, and D.K. Jeong. Evaluation of the antioxidant, anti-inflammatory, and anticancer activities of *Euphorbia hirta* ethanolic extract. *Molecules* 19: 14567-14581 (2014).
- 100.J. Chen, H. Er, S. Mohamed, and Y. Chen. In vitro anti-inflammatory activity of fractionated *Euphorbia hirta* aqueous extract on rabbit synovial fibroblasts. *Biomedical Journal* 38(4): 301-306 (2015).
- 101.G. Singh, P. Kaiser, M. Youssouf, S. Singh, A. Khajuria, A. Koul, S. Bani, B. Kapahi, N. Satti, and K. Suri. Inhibition of early and late phase allergic reactions by *Euphorbia hirta L. Phytotherapy Research* 20: 316-321 (2006).
- 102.S.F. Ahmad, S. Bani, P. Sultan, S.S. Ali, S.A. Bakheet, S.M. Attia, and A.R. Abd-Allah. TNF-α inhibitory effect of *Euphorbia hirta* in rats.

Pharmaceutical Biology 51: 411-417 (2013).

- 103.P.Y. Mali, and S.S. Panchal. *Euphorbia neriifolia* L.: Review on botany, ethnomedicinal uses, phytochemistry and biological activities. *Asian Pacific Journal of Tropical Medicine* 10: 430-438 (2017).
- 104.S. Datta, M.G. Kar, and S. Nayak Siva. Hepatoprotective activity of *Euphorbia neriifolia* against paracetamol induced hepatotoxicity in rats. *Der Pharmacia Lettre* 7: 23-28 (2015).
- 105.P. Bigoniya, and A. Rana. Subacute effect of *Euphorbia neriifolia* Linn. on hematological, biochemical and antioxidant enzyme parameters of rat. *Academic Journal of Plant Sciences* 2: 252-259 (2009).
- 106.S.A. Ahmed, S. Nazim, S. Siraj, P.M. Siddik, and C.A. Wahid. *Euphorbia neriifolia* Linn: A phytopharmacological review. *International Research Journal of Pharmacy* 2: 41-48 (2011).
- 107.P. Bigoniya, and A. Rana. Pharmacological screening of *Euphorbia neriifolia* leaf hydroalcoholic extract. *Journal of Applied Pharmaceutical Science* 1: 1-17 (2010).
- 108.M.I. Mansuri, and V.M.Patel. Anti-diabetic potential of *Euphorbia neriifolia* Linn. alloxan induced diabetic rats. *Journal of Pharmacy Research* 5: 2571-2573 (2012).
- 109.B.R. Thorat, and V. Bolli. Review on *Euphorbia* neriifolia plant. Biomedical Journal of Scientific and Technical Research 1(6): 1723-1732 (2017).
- 110.P. Bigoniya, and A.C. Rana. Radioprotective and in-vitro cytotoxic sapogenin from *Euphorbia neriifolia* (Euphorbiaceae) leaf. *Tropical Journal of Pharmaceutical Research* 8(6): 521-530 (2009).
- 111. K. Gaur, A. Rana, R. Nema, M. Kori, and C. Sharma. Anti-inflammatory and analgesic activity of hydroalcoholic leaves extract of *Euphorbia neriifolia* Linn. Asian Journal of Pharmaceutical and Clinical Research 2: 26-28 (2009).
- 112. P. Bigoniya, A. Shukla, and C.S. Singh. Dermal irritation and sensitization study of *Euphorbia neriifolia* latex and its anti-inflammatory efficacy. *International Journal of Phytomedicine* 2(3): 240-254 (2010).
- 113.M. Hasan, A. Ganeshpurkar, D. Bansal, and N. Dubey. Protective effect of *Euphorbia neriifolia* extract on experimentally induced thrombosis in murine model. *Nigerian Journal of Experimental* and Clinical Biosciences 2: 86-89 (2014).
- 114. P. Bigoniya, and A. Rana. Wound healing activity of *Euphorbia neriifolia* leaf ethanolic extract in rats. *Journal of Natural Remedies* 7: 94-101 (2007).
- 115.N. Uawonggul, A. Chaveerach, S. Thammasirirak, T. Arkaravichien, C. Chuachan, and S. Daduang. Screening of plants acting against Heterometrus laoticus scorpion venom activity on fibroblast cell lysis. *Journal of Ethnopharmacology* 103: 201-207 (2006).
- 116. K. Gaur, A. Rana, L. Chauhan, C. Sharma, R. Nema,

and M. Kori. Investigation of immunomodulatory potential of *Euphorbia neriifolia* Linn. Against betamethasone induced immunosuppression. *International Journal of Phytopharmacy Research* 2: 8-11 (2009).

- 117.P. Janmeda, V. Sharma, L. Singh, R. Paliwal, S. Sharma, S. Yadav, and S. Sharma. Chemopreventive effect of hydroethanolic extract of *Euphorbia neriifolia* leaves against DENA-induced renal carcinogenesis in mice. *The Asian Pacific Journal of Cancer Prevention* 12(3): 677-683 (2011).
- 118.J.X. Shi, Z.X. Li, T. Nitoda, M. Izumi, H. Kanzaki, N. Baba, K. Kawazu, and S. Nakajima. Three antinematodal diterpenes from *Euphorbia kansui*. *Bioscience, Biotechnology, and Biochemistry* 71: 1086-1089 (2007).
- 119.F. Cheng, Y. Yang, L. Zhang, Y. Cao, W. Yao, Y. Tang, and A. Ding. A natural triterpene derivative from *Euphorbia kansui* inhibits cell proliferation and induces apoptosis against rat intestinal epithelioid cell line in vitro. *International Journal of Molecular Sciences* 16: 18956-18975 (2015).
- 120.X. Yan, L. Zhang, Y. Cao, W. Yao, Y. Tang, and A. Ding. An ingenol derived from *Euphorbia kansui* induces hepatocyte cytotoxicity by triggering G0/ G1 cell cycle arrest and regulating the mitochondrial apoptosis pathway in vitro. *Molecules* 21: 813 (2016).
- 121.D.C. Cary, K. Fujinaga, and B.M. Peterlin. *Euphorbia kansui* reactivates latent HIV. *PloS one* 11: e0168027 (2016).
- 122.H. Jin-Jun, S. Yao, Y. Zhou, F. Lin, C. Lu-Ying, Y. Shuai, L. Hua-Li, W. Wan-Ying, and G. De-An. Anti-proliferation activity of terpenoids isolated from *Euphorbia kansui* in human cancer cells and their structure-activity relationship. *Chinese Journal* of Natural Medicines 15: 766-774 (2017).
- 123.K. Yasukawa, T. Akihisa, Z.Y. Yoshida, and M. Takido. Inhibitory effect of euphol, a triterpene alcohol from the roots of *Euphorbia kansui*, on tumour promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. *Journal of Pharmacy and Pharmacology* 52: 119-124 (2000).
- 124.J. Shi, M. Izumi, N. Baba, and S. Nakajima. Termiticidal activity of diterpenes from the roots of *Euphorbia kansui. Zeitschrift für Naturforschung* 63: 51-58 (2008).
- 125.S.W. Lee, H.Y. Na, M.H. Seol, M. Kim, and B.C.Lee. *Euphorbia kansui* attenuates insulin resistance in obese human subjects and high-fat diet-induced obese mice. *Evidence-Based Complementary and Alternative Medicine* 2017: 1-7 (2017).
- 126.L. Zhang, L. Gao, Z. Li, X. Yan, Y. Yang, Y. Tang, Y. Cao, and A. Ding. Bio-guided isolation of the cytotoxic terpenoids from the roots of *Euphorbia kansui* against human normal cell lines L-O2 and GES-1. *International Journal of Molecular Sciences* 13(9): 11247-11259 (2012).

- 127.Z.Y. Wang, H.P. Liu, Y.C. Zhang, L.Q. Guo, Z.X. Li, and X.F. Shi. Anticancer potential of *Euphorbia helioscopia* L extracts against human cancer cells. *The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology* 295: 223-233 (2012).
- 128.U. Saleem, B. Ahmad, M. Ahmad, K. Hussain, N.I. Bukhari, and M. Ashraf. Evaluation of anti-angiogenic activity of latex and extracts of *Euphorbia helioscopia* using chorioallontoic membrane (CAM) assay. *International Journal of Agriculture & Biology* 17(2): 339-344 (2015).
- 129.M. Ramezani, J. Behravan, M. Arab, and S.A. Farzad. Antiviral activity of *Euphorbia helioscopia* extract. *Journal of Biological Sciences* 8: 809-813 (2008).
- 130.A. Barla, H. Birman, S. Kültür, and S. Öksüz. Secondary metabolites from *Euphorbia helioscopia* and their vasodepressor activity. *Turkish Journal of Chemistry* 30: 325-332 (2006).
- 131.M.L.do.C. Caxito, C.P. Victório, H.B. Da Costa, W. Romão, R.M. Kuster, and C.R. Gattass. Antiproliferative activity of extracts of *Euphorbia tirucalli* L (Euphorbiaceae) from three regions of Brazil. *Tropical Journal of Pharmaceutical Research* 16: 1013-1020 (2017).
- 132.P. Palit, D. Mukherjee, P. Mahanta, M. Shadab, N. Ali, S. Roychoudhury, M. Asad, and S.C. Mandal. Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of *Euphorbia tirucalli* Linn root in experimental in vitro and in vivo model. *Inflammopharmacology* 26: 235-250 (2018).
- 133.M. Prabha, C. Ramesh, I. Kuppast, and K. Mankani. Studies on anti-inflammatory and analgesic activities of *Euphorbia tirucalli* L. latex. *International Journal of Chemical Sciences* 6: 1781-1787 (2008).
- 134.C. Ramesh, M. Prabha, S. Deepak, and K. Madhusudhan. Screening of antiviral property against tobamoviruses in latex of *Euphorbia tirucalli* L. *Indian Journal of Biotechnology* 3: 1-3 (2009).
- 135.R.C. Dutra, K.A.B.S. da Silva, A.F. Bento, R. Marcon, A.F. Paszcuk, F.C. Meotti, L.F. Pianowski, and J.B. Calixto. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: The involvement of cannabinoid system. *Neuropharmacology* 63: 593-605 (2012).
- 136.A.N. Harpalani, A.D. Taranalli, K.V. Otari, R.V. Karadi, and R.V. Shete. An antiinflammatory and anti-arthritic potential of aqueous and alcoholic extract of *Euphorbia antiquorum* Linn. *Pharmacologyonline* 2: 287-298 (2011).
- 137.N.U. Islam, I. Khan, A. Rauf, N. Muhammad, M. Shahid, and M.R. Shah. Antinociceptive, muscle relaxant and sedative activities of gold nanoparticles

generated by methanolic extract of Euphorbia milii. *BMC Complementary and Alternative Medicine* 15: 1-11 (2015).

- 138.A. Rauf, N. Muhammad, M. Qaisar, G. Uddin, and I. Hussain. Preliminary antinociceptive studies of methanol extract of *Euphorbia milli*. *Middle-East Journal of Medicinal Plants Research* 1: 68-70 (2012).
- 139.B. Sermsart, S. Sripochang, T. Suvajeejarun, and R. Kiatfuengfoo. The molluscicidal activities of some *Euphorbia milii* hybrids against the snail Indoplanorbis exustus. *Southeast Asian Journal* of *Tropical Medicine and Public Health* 36: 192 (2005).
- 140.A. Rauf, M. Jan, W. Rehman, and N. Muhammad. Phytochemical, phytotoxic and antioxidant profile of Caralluma tuberculata NE Brown. *Wudpecker Journal of Pharmacy and Pharmacology* 2: 21-25 (2013).
- 141.A. Yakubu, and M. Mukhtar. In vitro antimicrobial activity of some phytochemical fractions of Euphorbia pulcherima L.(Poinsettia). Journal of Medicinal Plants Research 5: 2470-2475 (2011).
- 142.K.K. Singh, G.P. Rauniar, and H. Sangraula. Experimental study of neuropharmacological profile of *Euphorbia pulcherrima* in mice and rats. *Journal of Neurosciences in Rural Practice* 3: 311-319 (2012).
- 143.S. Özbilgin, O.B. Acıkara, E.K. Akkol, I. Süntar, H. Keleş, and G.S. İşcan. In vivo woundhealing activity of Euphorbia characias subsp. wulfenii: Isolation and quantification of quercetin glycosides as bioactive compounds. *Journal of Ethnopharmacology* 224: 400-408 (2018).
- 144.D.G. Davis. Polyamines, auxins and organogenesis in leafy spurge (*Euphorbia esula* L.). *Journal of Plant Physiology* 151: 603-609 (1997).
- 145.Y. Yamamoto, R. Mizuguchi, and Y. Yamada. Chemical constituents of cultured cells of *Euphorbia tirucalli* and *E. millii*. *Plant Cell Reports* 1: 29-30 (1981).
- 146.Y. Yamamoto, N. Kadota, R. Mizuguchi, and Y. Yamada. Computer tracing of the pedigree of cultured *Euphorbia millii* cells that produce high levels of anthocyanin. *Agricultural and Biological Chemistry* 47: 1021-1026 (1983).
- 147.Y. Yamamoto, Y. Kinoshita, S. Watanabe, and Y. Yamada. Anthocyanin production in suspension cultures of high-producing cells of *Euphorbia millii*. *Agricultural and Biological Chemistry* 53: 417-423 (1989).
- 148.G.P. Kumar, M. Vijila, and R. Paul Raj. Early callus induction and batch kinetics studies for in vitro production of triterpenoids in suspension cultures of *Euphorbia hirta* Linn. *Drug Invention Today* 10: 3266-3271 (2018).

ANNEXURE I

 Table 1. Various pharmacological attributes of the genus Euphorbia.

| Species | Part used | Extract type | Pharmacological activities | Study type | Dose | Animal model/Cell line | References |
|--|----------------|--|--|-----------------|----------------------------|-----------------------------|------------|
| | Whole plant | AqE | Anti-arthritis | | 50 mg/kg | Rats | [57] |
| Species - </td <td>Leaves</td> <td>AqE</td> <td>Immunomodulatory</td> <td></td> <td>50 g/kg</td> <td>Fish</td> <td>[58]</td> | Leaves | AqE | Immunomodulatory | | 50 g/kg | Fish | [58] |
| | Whole plant | HAE | Anxiolytic | | 200 mg/kg | Rats | [59] |
| | Whole plant | EtOH | Anti-nephrotoxicity | nrotoxicity | | Rats | [60] |
| | Leaves | AqE | Anti- gastrointestinal motility | | 100 mg/kg to 1000 mg/kg | Rats | [61] |
| | Whole plant | EtOH | Wound Healing | | 2% w/w | Rats | [62] |
| Species E. hirta E. neri- ifolia | Whole plant | EtOH | Bronchodilator | | 200 mg/kg | Animal | [31] |
| | Leaves | МеОН | Acute oral toxicity | - | 100 mg/mL to 0.07 mg/mL | Mice | [34] |
| E. hirta | Whole Plant | EqOH | Anti-dengue | • | 12.5 μg/mL | Human | [63] |
| | Whole Plant | EtOH | Anti-anaphylaxis | | 100 mg/kg to 1000 mg/kg | Mice | [64] |
| | Leaves | AqE | Anti-diabetic | In-vitro | 300 mg/kg | Rats | [65] |
| | Whole Plant | AqE | Sedative | | 100 mg/kg | Mice | [66] |
| | Whole Plant | MeOH | Anti-biofilm | | 0.25 mg/mL | Planktonic cells | [67] |
| | Whole plant | EtOH | Wound healing | | 2% W/W cream. | Albino rats | [62] |
| | Aerial parts | МеОН | Anti-bacterial | _ | 0.25 mg/mL to 0.5 mg/mL | Pseudomonas aeru- ginosa | [67] |
| | Leaves | EtOH | Anti-bacterial | | 1.25 μg/mL to 200 μg/mL | Klebsiella pneu- moniae | [68] |
| | Whole plant | EtOH | Anti-cancer | | 200 µg/mL | Cell lines | [69] |
| | Whole plant | Aq | Anti-inflammatory | _ | 10 μg/mL | Rabbit | [70] |
| | Whole plant | EtOH | Anti-allergic | | 0.3 mg/g | Mice | [71] |
| | Aerial parts | MeXOH | Antidiarrheal | | 50 mg/kg | Mice | [5] |
| | Leaves | MeOH | Anti-tumors | - | 200 mg/kg | Rats | [72] |
| | Leaves | HAE | Analgesic | In-vitro | 400 mg/kg | Frog | [73] |
| | Stem | МеОН | Hepatoprotective | Labora- tory | 2.0 g/kg | Mice | [74] |
| SpeciesPart usedEXTRA typeFull matchington activitiesStudy typeDoseWhole plantAqEAnti-arthritis50 g/kgLeavesAqEImmunomodulatory200 mg/kgWhole plantEtOHAnti-nephrotoxicity400 mg/kgWhole plantEtOHAnti-rephrotoxicity100 mg/kgWhole plantEtOHAnti-rephrotoxicity200 mg/kgWhole plantEtOHBronchodilator200 mg/kgWhole plantEtOHBronchodilator200 mg/kgLeavesMcOHAcute oral toxicity300 mg/kgWhole PlantEqOHAnti-dangue100 mg/kgUhole PlantAqESedative300 mg/kgWhole PlantAqESedative300 mg/kgWhole PlantEtOHAnti-biofilm 22% W/WWhole PlantEtOHAnti-biofilm 22% W/WLeavesAqEAnti-biofilm 0.25 mg/mLWhole PlantEtOHAnti-bacterial 0.25 mg/mLWhole plantEtOHAnti-cancer 200 mg/kgWhole plantEtOHAnti-atilarris 0.25 mg/mLLeavesMeOHAnti-atilarrikal 0.25 mg/mLLeavesMeOHAnti-atilarrikal 0.25 mg/mLLeavesHAEAnti-utoros 200 mg/kgLeavesHAEAnti-utoros 200 mg/kgLeavesHAEAnti-utoros 200 mg/kgLeavesHAEImmunomodulatory 400 mg/kgLeaves <td< td=""><td>Mice</td><td>[75]</td></td<> | Mice | [75] | | | | | |
| | Leaves | Part usedExtract typePharmacological activitiesStudy typeDoseAnimal PoseAnimal PoseAnimal PoseAnimal PoseAnimal PosePosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal PosePoseAnimal | Rats | [76] | | | |
| SpeciesPart useWhole planLeavesWhole planWhole planWhole planLeavesWhole planLeavesWhole planUhole planWhole planWhole planWhole PlanLeavesWhole PlanLeavesWhole PlanWhole PlanWhole planWhole planWhole planWhole planWhole planWhole planWhole planKeavesLeaves< | Leaves | HAE | Anti-ulcer | In-vitro | 400 mg/kg | Rats | [77] |
| | Leaves | EtOH | Anti-diabetic | | 400 mg/kg | Rats | [78] |
| | Leaves | EtOH | Anti-anxiety | | 400 mg/kg | Mice | [79] |
| E neri- | Leaves | HAE | Hematological | | 400 mg/kg | Rats | [51] |
| E. hirta E. neri- ifolia | Leaves | HAE | analgesic | Labora- tory | 400 mg/kg | Rats | [80] |
| | Latex | EF | Anti-inflammatory | - | 500 mg/mL | Rats | [81] |
| | Roots & Leaves | EtOH | Anti-thrombotic | In-vitro | 2.0 mg/kg | Rats | [82] |
| | Leaves | EtOH | Wound healing | Labora- | 200 mg/kg and 400 mg/kg | Rats | [83] |
| | Leaves | AqE | Anti-scorpion venom | tory | 0.706 mg/mL | Fibroblast cell lysis | [84] |
| | Leaves | HAE | Immunomodulatory | | 400 mg/kg | Rats | [85] |
| | Leaves | HEE | Anti-DENA-Induced Renal Carcinoge- nesis | In-vivo | 50 mg/kg | Mice | [86] |

| Species | Part used | Extract type | Pharmacological activities | Study type | Dose | Animal model/Cell line | References |
|---|------------------|--|-------------------------------|--|----------------------------|--|------------|
| | Roots | EtOH | Anti-nematode | _ | 5 µg | Bursaphelenchus xylophilus | [87] |
| | Roots | EtOH | Anti-proliferative | Study type Dose Animal model/Cell line Reference xylophilus Reference(87) 5 µg Bursaphelenchusxylophilus [87] 8.7 µg/mL Cell lines [88] 8.7 µg/mL Cell lines [88] 90] 500 µg/mL Human [90] 50 µg/mL Human [91] 2.0 µmol Mice [92] 50 µg/mL Reticulitermessperatus [93] 100 mg/kg Mice [94] 30.67 µg/mL Cell lines [95] [93] In-vitvo 200 µg/mL Cell lines [95] In-vitvo 200 µg/mL Cell lines [96] 30 mg/kg Pig [97] [97] Labora-tory 10 ppm to 100ppm Snail [100 0.125 mg/mL Bacteriophage(CP51) [101 2.00 mg/kg Mice [104] 2.00 mg/kg Mice [104] 2.00 mg/kg Mice [104] <t< td=""><td>[88]</td></t<> | [88] | | |
| Species $F. kan Sui$ $E. kan Sui$ Ri $Iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii$ | Roots | EtOH | Hepatotoxic | - | 8 μg/mL | Cell lines | [89] |
| E kan- | Roots | sedExtract typePharmacological activitiesStudy typeDoseAnimal mode lineEtOHAnti-nematode $5 \ \mu g$ $BursaphelenclxylophilusBursaphelenclxylophilusEtOHAnti-proliferative8 \ \pi \mu g/mLCell linesEtOHAnti-cancer500 \ \mu g/mLHumanDCMEAnti-cancer500 \ \mu g/mLHumanEtOHAnti-cancer50 \ \mu g/mLHumanEtOHAnti-obesity100 \ m g/kgMiceEtOHAnti-obesity100 \ m g/kgMiceantEAEAnti-ancerIn-vivo200 \ \mu g/mLantEAEAnti-ancerIn-vivo200 \ \mu g/mLCell linesantEAEAnti-ancerIn-vivo200 \ \mu g/mLCell linesantEAEAnti-ancerIn-vivo200 \ \mu g/mLLeghorn chickeggsddMeOHAnti-angiogenicIn-vivo200 \ \mu g/mLLeghorn chickeggsadMeOHAnti-viral0.125 \ m g/mLBacteriophag(CPS1)antMeOHAnti-oxidantIn-vivo10 \ pm/mLBacteriaidMeOHAnti-cancer1n-vivo200 \ m g/kgRatsidMeOHAnti-oxidantIn-vivo1200 \ mg/kgMiceantMeOHAnti-oxidantIn-vivo10 \ pm/mLCell linesidMeOHAnti-oxidantIn-vivo1200 \ mg/kgMiceidMeOH$ | Human | [90] | | | |
| Species E. kan- sui E. he- liosco- pia E. tiru- calli E. anti- quorum | Roots | EtOH | Anti-cancer50 µAnti-cancer2.0 | | 50 μg/mL | Human | [91] |
| | Roots | DCME | | | 2.0 μmol | Mice | [92] |
| | Roots | EtOH, | Anti-termites | Immacological activitiesStudy typeDoseAnimal model/Cell lineReferencenematode $5 \ \mu g$ Bursaphelenchus xylophilus[87]proliferative totoxic $8.7 \ \mu g/mL$ Cell lines[88]totoxic n_rvirro $50 \ \mu g/mL$ Cell lines[89]HIV cancer n_rvirro $50 \ \mu g/mL$ Human[90]cancer $50 \ \mu g/mL$ Human[91]cancer $2.0 \ \mu mol$ Mice[92]termites $50 \ \mu g/mL$ Reticulitermes speratus[93]obesity100 mg/kgMice[94]oxic $30.67 \ \mu g/mL$ Cell lines[95]cancer ln_rviro $200 \ \mu g/mL$ Cell lines[96]angiogenic ennetic ln_rviro $200 \ \mu g/nL$ Cell lines[96] $30 \ mg/kg$ Pig[97][99]steicidalLabora- tory $200 \ \mu g/L$ Leghorn chicken eggs[98]steicidalLabora- tory $10 \ pm to 100$ ppmSnail[100]viral $0.125 \ mg/mL$ Bacteriophage (CP51)[101]depressor $2.0 \ mg/kg$ Mice[104]cancer $00 \ mg/kg$ Mice[104]cancer $200 \ mg/kg$ Mice[104]cancer $00 \ mg/kg$ Mice[104]cancer $00 \ mg/kg$ Mice[104]cancer $00 \ mg/kg$ Mice[104]cancer $00 \ mg$ | [93] | | |
| | Roots | EtOH | Anti-obesity | - | 100 mg/kg | Mice | [94] |
| | Roots | EtOH | Cytotoxic | | 30.67 μg/mL | Cell lines | [95] |
| | Whole plant | EAE | Anti-cancer | In-vivo | 200 µg/mL | Mice | [88] |
| | Whole plant | EAE | Anti-cancer | In-vitro | 200 μg/mL | Cell lines | [96] |
| | Whole plant | EAE | Anti-asthmatic | - | 30 mg/kg | Pig | [97] |
| E. he- liosco- pia | Leaves and latex | MeOH | Anti-angiogenic | In-vivo | 200 µg/L | Leghorn chicken eggs | [98] |
| | Plant | MeOH & AqE | Anthelmintic | - | 50mg/mL | Haemonchus von- tortus | [99] |
| | Leaves and stem | MeOH | Molluscicidal | Labora- tory | 10 ppm to 100 ppm | Snail | [100] |
| | Whole plant | MeOH | Anti-viral | | 0.125 mg/mL | Bacteriophage (CP51) | [101] |
| | Aerial parts | MeOH | Vasodepressor | | 2.0 mg/kg | Rats | [102] |
| | Leaves | MeOH | Anti-pyretic | | 300 mg/kg | Mice | [103] |
| | Leaves and latex | МеОН | Anti-bacterial | _ | 250 mg/mL | Bacteria (S. aureus and E. coli) | [104] |
| E. kan- sui | Leaves and latex | MeOH | Anti-oxidant | In-vitro | 1200 mg/kg | Mice | [96] |
| | Whole plant | EAE | Anti-cancer | | 200 mg/mL | Cell lines | [105] |
| | Roots | AqE | Anti-tumor | - | 4.0 mg/mL | MKN-45 cells | [106] |
| | Whole plant | EtOH | Insulin secretagogue | - | 10 μg/mL | Mice | [107] |
| | Stem | EtOH | Anti-cancer | - | 300.70 μg/mL | Cell lines | [108] |
| E. kan- sui | Leaves | AqE | Anti-cancer | - | 200 µg/mL | Cell lines | [109] |
| | Whole plant | EAE | Anti-inflammatory | In-vivo | 10 mg/kg | Mice | [110] |
| E. tiru- | Latex | AqE | Analgesic | | 300 mg/kg | Mice | [111] |
| E. tiru- calli | Whole plant | BET | Anti-arthritic | - In vivo | 2000 mg/kg | Mice and rats | [112] |
| | Aerial parts | AqE | Hepatoprotective | <i>In-vivo</i> | 150 mg/kg and 250 mg/kg | Rats | [113] |
| | Latex | PEE & DCME | Antiviral | | 150 ppm | Tobamoviruses | [114] |
| | Whole plant | MeOH | Antinociceptive | In-vivo | 30 mg/kg | Mice | [115] |
| | Roots | AqE | Anti-diabetes | In-vitro | 400 mg | Rats | [116] |
| E. anti- | Whole plant | A-EtOH | Analgesic | Labora- tory | 500 mg/kg | Mice | [117] |
| quorum | Whole plant | AEA & AqE | Anti-arthritic | | 400 mg/kg | Rats | [118] |

| Species | Part used | Extract type | Pharmacological activities | Study type | Dose | Animal model/Cell line | References |
|--|-----------------|--------------------------|--|-----------------|---|---------------------------|------------|
| Species E. millli | Flower | EAE | Anti-cancer | In-vivo | 200 mg/kg and 400 mg/kg | Mice | [119] |
| E millli | Aerial parts | МеОН | Extract typePharmacological activitiesStudy typeDoseAnimal model/Cell lineEAEAnti-cancerIn-vivo200 mg/kg and 400 mg/kgMiceMeOHSedative10 ppm and 20 mg/kgMiceMeOHAntinociceptive50 mg/kg, 100 mg/kgMiceMeOHAntinociceptive50 mg/kg, 100 mg/kgMiceAqEMolluscicidal22 ppm (mg/L)SnailAqEMolluscicidal0.02 mg/kg and 0.09 mg/LSnailAqEAnti-convulsiveLabora- tory50 mg/kg, 100 mg/kg and 150MiceMeOHAnalgesic effect50 mg/kg, 100 mg/kgMiceAqE and EIOHAntimicrobialIn-vitro2000 µg to 500 mg/kg, 500 mg/kg and 1000 mg/kgE. coli and A. nigerAqEAnxiolytic effect250 mg/kg, 500 mg/kg and 1000 mg/kgMiceAqEAnxiolytic effect250 mg/kg, 500 mg/kg and | [120] | | | |
| Species <i>E. millli</i> <i>E. pulcher-rima</i> <i>E. chara-cias</i> | Aerial parts | МеОН | Antinociceptive | | 50 mg/kg, 100 mg/kg and 150 mg/kg | Mice | [121] |
| | Latex | AqE | Molluscicidal | | 22 ppm (mg/L) | Snail | [122] |
| E. pulcher- rima | Latex | AqE | Molluscicidal | | 0.02 mg/kg and 0.09 mg/L | Snail | [123] |
| | Latex | AqE | Anti-convulsive | Labora- tory | 250 mg/kg, 500 mg/kg and 1000 mg/kg | Mice | [124] |
| | Aerial parts | МеОН | Analgesic effect | | 50 mg/kg,100 mg/kg and 150 mg/kg | Mice | [125] |
| | Whole plant | AqE and EtOH | Antimicrobial | In-vitro | 2000 µg to 5000 µg | E. coli and A. niger | [126] |
| | Latex | AqE | Anxiolytic effect | | 250 mg/kg, 500 mg/kg and 1000 mg/kg | Mice | [127] |
| | Whole plant | MeOH | Hepatoprotective | | 1000 mg/kg | Rats | [67] |
| | Latex | MeOH | Antioxidant | | 25 μL | DPPH | [128] |
| | Aerial parts | MeOH | Anti-inflammatory | In-vivo | 100 mg/kg | Rats | [32] |
| E. pulcher rimaAerial partsMeOHAnalgesic effect $1000 \text{ mg}}{1000 \text{ mg}}$ Whole plantAqE and EtOHAntimicrobial $In-vitro$ $2000 \mu g$ $5000 \mu g$ LatexAqEAnxiolytic effect $250 \text{ mg}}{1000 \text{ mg}}$ LatexAqEAnxiolytic effect $2000 \mu g$ $5000 \mu g$ LatexAqEAnxiolytic effect $2000 \mu g$ $5000 \mu g$ LatexMeOHHepatoprotective $1000 \text{ mg}}{1000 \text{ mg}}$ LatexMeOHAnti-inflammatory $In-vivo$ $1000 \text{ mg}}{1000 \text{ mg}}$ LeavesEtOHAnti-inflammatory $In-vivo$ $100 \text{ mg}}{1000 \text{ mg}}$ LatexMeOHMeOHAnti-bacterial \dots $1250 \mu g$ tein/mLLatexLatexAnti-bacterial \dots $1250 \mu g$ tein/mL | 1250 µg/mL | Staphylococcus aureus | [36] | | | | |
| | Aerial parts | МеОН | Wound healing | In-vivo | | Rats | [129] |
| | Latex | | Antifungal | In-vitro | 62.5 μg pro- tein/mL | Candida albicans | [130] |

ANNEXURE II

Table 2. A list of explants used growth regulators and reported basal media for *in-vitro* propagation of *Euphorbia* species.

| Species | Explant | PGRs | Culture Medium | Responses | References |
|--|----------------------------------|--|--|--|------------|
| | Stem explant | BA + IBA + 3% sucrose + vitamins | MS | Shoot | [29] |
| | Hypocotyl segment | IAA + 2,4-D | В5 | Shoots and Roots | [131] |
| | Root tissue | NAA + KIN + IAA | MS | Callus | [35] |
| E. esula | Cell suspension culture | 2,4-D+NR | B5 | Roots | [132] |
| | Hypocotyl segments. | IAA + polyamines | В5 | Roots | [133] |
| | Hypocotyl segments. | Putrescine | В5 | Roots and shoots | [45] |
| | Stem callus | Fluorescent light | MS | ResponsesReferencesShoots and Roots[131]Shoots and Roots[132]Roots[132]Roots[133]Roots and shoot[45]Cell suspension[131]Roots[40]Callus[134]Galus[134]Galus[134]AB[54]Inflorescence[56]Roots[136]Shoot[44]Shoot[138]Shoot[139]Shoot[140]SE[140]SE[140]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[142]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[143]Shoot[30]Shoot[30]Shoot and callus[34]Shoot and callus[34]Shoot and callus[34] | |
| E. lagascae | Axillary shoots | IBA or NAA | MS | Roots | [40] |
| | Stem | BA, NAA, 2,4-D | MS | Callus | [134] |
| E. tirucalli | Internode | TDZ, NAA | LS medium | AB | [135] |
| | Internode | TDZ | LS | AB | [54] |
| F milli | Apical bud | Paclobutrazol + Sucrose + LEDs | MS | Inflorescence | [56] |
| <i>E. milli</i> | Buds | BA+ IAA+ Sucrose + vitamins | MS | Roots | [136] |
| | Nodal shoot segments | BAP+ GA3+AS | MS | Shoot | [44] |
| E. esula Stem explant I AA = 2,4-D Root tissue NAA + KIN + IAA Cell suspension culture 2,4-D+NR Hypocotyl segments. IAA + polyamines Hypocotyl segments. IAA + polyamines Hypocotyl segments. IAA + polyamines Hypocotyl segments. Putrescine Stem callus Fluorescent light E. lagascae Axillary shoots IBA or NAA Stem BA, NAA, 2,4-D E. tirucalli Internode TDZ Apical bud Paclobutrazol + Sucrose vitamins Nodal shoot segments BAP+ GA3+AS Apical buds and axillary buds BA+ tAA+ Sucrose vitamins Nodal shoot segment BAP+ GA3+AS Apical buds and axillary buds BA+ sucrose (3%) + 4 (75%) Terminal buds and Leaf tissue Stem nodes NAA + 2-Ip Hypocyle segment IAA CS 2,4-D + BA Stem nodal explants BAP+ NAA Stem nodal explants BAP+ NAA Stem nodal explants BAP+ NAA Stem nodal explants BAP + NAA E. nivulia Mesophyll cell NAA + BA + sucros E. antisyphilitiea Shoot BA + NAA E. hitra Leaf bits NAA + BAP E. helioscopa Leaf discs 2,4-D E. lathyris Apical shoot NAA NAA + BAP E. helioscopa Leaf discs 2,4-D E. lathyris Apical shoot NAA NAA + BAP E. helioscopa Leaf discs 2,4-D Shoot NAA + BAP E. helioscopa Leaf discs 2,4-D Apical shoot NAA + BAP Stem NAA + BAP Stem explants BAP + KIN + NAA Stem expl | IAA+BA | MS | Callus | [137] | |
| | Shoot tips | HorseMediumResponsesReference $BA + IBA + 3\%$ sucrose + vitaminsMSShoots and Roots[29] $IAA + 2,4-D$ B5Shoots and Roots[131] $NAA + KIN + IAA$ MSCallus[35] $2,4-D+NR$ B5Roots[132] $IAA + polyamines$ B5Roots[133] $Putrescine$ B5Roots and shoots[45]Fluorescent lightMSCell suspension[131]IBA or NAAMSRoots[40]BA, NAA, 2,4-DMSCallus[134]TDZ, NAALS mediumAB[135]TDZLSAB[54]Paclobutrazol + Sucrose + LEDsMSInflorescence[56]BA+ IAA + Sucrose + vitaminsMSRoots[138]BAP+ GA3+ASMSShoot[44]IAA+BAMSCallus[137]BA + sucrose (3%) + agar | [138] | | |
| | Nodal explant | 2ip + NAA | MS | SE | [139] |
| | Shoot | BA+ sucrose (3%) + agar (75%) | MS Shoots and Roots [131] MS Callus [35] B5 Roots [132] B5 Roots [133] B5 Roots and shoots [45] MS Cell suspension [131] MS Cell suspension [131] MS Cell suspension [131] MS Callus [134] LS AB [135] LS AB [136] MS Inflorescence [56] MS Roots [137] MS Shoot [44] MS Shoot [44] MS Shoot [46] MS Shoot [141] MS Shoot [142] MS Shoot [141] MS Shoot [141] | | |
| E. pulcherrima | Terminal buds and Leaf tissue | IAA + BA | MS | Callus and Shoot | [53] |
| | Stem nodes | NAA+2-Ip | MS | SE | [26] |
| | Hypocotyle segment | IAA | MS | SE | [140] |
| | CS | 2,4-D + BA | MS | SE | [141] |
| | [142] | | | | |
| | Petiole explants | NAA + BA+ KIN +2,4-D+IBA+IAA | MS | Buds | [142] |
| E. pugniformis | Tip explants | NAA + BA + sucrose | MS | Shoot | [41] |
| E. antisyphilitiea | Shoot | BA + NAA | MS | Axillary shoot | [143] |
| E. nivulia | Mesophyll cell | NAA | MS | Shoot | [17] |
| E hitra | Stem explants | BAP + KIN + NAA | MS | SE | [55] |
| L. mura | Leaf bits | NAA+ BAP | MS | Callus | [30] |
| E. helioscopa | Leaf discs | 2,4-D | MS | Callus | [38] |
| E lathania | Apical shoot | NAA | MS | AS | [39] |
| L. luinyris | Nodes and internodes | NAA+ BA | MS | Shoot and callus | [144] |

ANNEXURE III

| | | J | | 0 | 11 | | |
|--------------------------|----------------------|--------------------------|------------------------------|-----------|------------|------|--|
| Secondary Metabolites | Species | Culture Types | PGRs | Medium | References | | |
| Phytosterols | | | 2,4-D, NAA, ME | | [145] | | |
| Triterpenol | - | LC | Auxin, 2,4-D, NAA, YE | | | | |
| | - | | 2,4-D, NAA, CH | | | | |
| Antheoryonin | E. milli | CC | 2,4-D, NAA | | [146] | | |
| Anthocyanin | | LC | 2% sucrose, 0.8% agar, 2,4-D | | [146] | | |
| | | | MS, LS, GA, NN, HE, ME, | | [147] | | |
| | | | sucrose, | MS | | | |
| Phytosterols | | SC | ME, 2,4-D | | [62] | | |
| Fatty Acids | cids E triucall: | | YE, 2,4-D | | [03] | | |
| Anthocyanin | ocyanin E. triucalli | E. triucani ME, 2,4-D | | ME, 2,4-D | | [50] | |
| Triterpenol | - | | ME, 2,4-D | | [30] | | |
| Triterpenol | E. characias | CC | KIN, BA, ZEA, 2,4-D | | [52] | | |
| Taraxerol | E bists | | NAA, BAP | | [34] | | |
| Triterpenoid | penoid E. nirta | | 2,4-D+BAP+NAA | | [148] | | |

Table 3. In-vitro production of secondary metabolites from Euphorbia species via using different approaches.